What does AOD-9604 do?

Growth hormone does many things — it builds muscle, mobilises fat, affects blood sugar, and promotes cell growth. AOD-9604 was designed to isolate just the fat-mobilisation part. It’s a modified fragment of GH (amino acids 177–191 with a tyrosine addition) that stimulates lipolysis (fat breakdown) and inhibits lipogenesis (new fat formation) — without affecting blood sugar or IGF-1 levels.

In animal studies, this selectivity worked well. Obese mice lost significant fat mass without changes in glucose metabolism. In human trials, the results were mixed — some studies showed modest fat loss, others didn’t reach statistical significance. The compound did not achieve regulatory approval for obesity.

Despite this, AOD-9604 has gained popularity in the peptide community as a lower-risk approach to body fat reduction — the idea being that even a modest effect without GH side effects is worthwhile.

Who uses it?

• Body composition focus — people wanting fat loss without the insulin resistance risk of full GH therapy
• Stacking with other peptides — combined with GH-releasing peptides for complementary effects
• Those avoiding IGF-1 elevation — AOD-9604 does not raise IGF-1, which matters for people concerned about cancer risk
• GLP-1 alternatives — some explore it as a less aggressive approach than semaglutide

What to know before trying

Fasting state: Inject on an empty stomach, typically in the morning. Fasting optimises the lipolytic environment. Some protocols use it before fasted cardio.

No IGF-1 monitoring needed: Unlike other GH peptides, AOD-9604 does not raise IGF-1. This simplifies monitoring but also means you can’t use IGF-1 as a response marker.

Measuring results: Track body composition changes (waist circumference, DEXA) rather than scale weight. Effects, if present, are gradual over 8–12 weeks.

Frequently Asked Questions

How it works in your body

AOD-9604 stimulates lipolysis by activating the beta-3 adrenergic receptor pathway in adipose tissue — the same pathway activated by the fat-mobilising region of full GH. It also inhibits lipogenesis, preventing new fat formation. Critically, it does not activate the IGF-1 pathway or affect glucose metabolism, as these functions reside in different regions of the GH molecule.

What the studies show

• Animal studies: Significant fat mass reduction in obese mouse models without glucose metabolism changes
• Human trials: Mixed results. Some showed modest fat loss, others did not reach statistical significance. Conducted primarily in Australia.
• Safety: Well-tolerated in human trials. No significant adverse events. No blood sugar disruption.
• Did not achieve approval: Failed to meet regulatory endpoints for obesity treatment

What to monitor

• Body composition — waist circumference, DEXA, or consistent progress photos
• No IGF-1 monitoring needed — AOD-9604 does not affect IGF-1
• Metabolic panel — optional baseline to confirm no metabolic effects in your case

Side effects & safety

AOD-9604 has a favourable safety profile based on human trial data:

• Injection site reactions — redness, tenderness, or mild bruising. Standard subcutaneous injection effects.
• Headache — reported by some users, usually mild and limited to initial use.
• No blood sugar effects — confirmed in human trials. Does not cause insulin resistance.
• No IGF-1 elevation — no growth-promoting or cancer-risk concerns associated with IGF-1.
• No prolactin or cortisol effects — unlike GHRPs, AOD-9604 does not affect these hormones.
• Modest efficacy — the main "side effect" is that it may not produce noticeable fat loss in many users.

Who should be cautious: People who expect AOD-9604 to replace proper nutrition and exercise. It’s not a substitute for caloric deficit. Pregnant or breastfeeding women should avoid it.

Related